NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
20/02/2024
Voltar para busca
Dado oficial do USPTO
THE SUSTAINABLE HEALTHCARE CO
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
THE SUSTAINABLE HEALTHCARE CO
ST13
US500000090863643Classe
5, 35
Pedido
90863643
Registro
7311964
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
20/02/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35
Data de depósito
03/08/2021
Data de registro
20/02/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/02/2024
Última transação
20/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Supplemental Register
Fundamento do pedido
Intent to use
Primeiro uso
18/11/2022
Primeiro uso no comércio
18/11/2022
Código do desenho
4
Tipo de titular
03
Localização do titular
Washington, D. C., DC, US
Examinador
MCBRIDE, CAMERON L
Unidade examinadora
L60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Patel & Gong, Inc.
Representantes
Francis G. Gleason Jr. GLEASON & GLEASON P. C.
Classificação técnica
Classes Nice
Classe 5Classe 35
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorderssports related injuriesfor knee cartilage regeneration; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparationsanticoagulants; Pharmaceutical preparationsantidepressants; Pharmaceutical preparationsantivirals; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparationsa topical preparation for the treatment of ocular disorders prescribed by ophthalmologistseye surgeonsoptometrists; Pharmaceutical preparationsan analgesic for human consumption taken orally; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent swelling in the legs
Classe 35
Retail pharmacy services; Retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; Wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
20/02/2024
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
17/01/2024
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
16/01/2024
IUAA
USE AMENDMENT ACCEPTED
16/01/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
26/12/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
26/12/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
26/12/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
26/12/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/08/2023
GNRT
NON-FINAL ACTION E-MAILED
28/08/2023
CNRT
NON-FINAL ACTION WRITTEN
28/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/08/2023
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
09/08/2023
IUAF
USE AMENDMENT FILED
09/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/08/2023
EAAU
TEAS AMENDMENT OF USE RECEIVED
08/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/05/2023
GNRT
NON-FINAL ACTION E-MAILED
08/05/2023
CNRT
NON-FINAL ACTION WRITTEN
08/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/04/2023
ALIE
ASSIGNED TO LIE
20/04/2023
NREV
NOTICE OF REVIVAL - E-MAILED
24/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/01/2023
PETG
PETITION TO REVIVE-GRANTED
23/01/2023
PROA
TEAS PETITION TO REVIVE RECEIVED
23/01/2023
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
21/11/2022
MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
21/11/2022
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
21/11/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/05/2022
GNRT
NON-FINAL ACTION E-MAILED
06/05/2022
CNRT
NON-FINAL ACTION WRITTEN
06/05/2022
DOCK
ASSIGNED TO EXAMINER
29/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/10/2021
NWAP
NEW APPLICATION ENTERED
06/08/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace THE SUSTAINABLE HEALTHCARE CO ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.